Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases.
Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases.
复制标题
DOI：
10.1002/acr.22600
复制
发表时间：
2016-01
影响因子：
4.7
通讯作者：
Mammen AL
中科院分区：
文献类型：
--
作者：
Lloyd TE;Christopher-Stine L;Pinal-Fernandez I;Tiniakou E;Petri M;Baer A;Danoff SK;Pak K;Casciola-Rosen LA;Mammen AL
先前的研究表明，在33-76%的包涵体肌炎（IBM）患者中发现了识别胞质5′-核苷酸酶1A（NT 5C 1A）的自身抗体，但在多发性肌炎（PM）患者中很少观察到。因此，抗NT 5C 1A可能有助于区分IBM和PM。虽然4-21%的皮肌炎（DM）患者显示抗NT 5C 1A抗体阳性，但抗NT 5C 1A阳性DM患者的临床特征尚未被描述。此外，抗NT 5C 1A抗体在其他风湿性疾病中的患病率尚未报道。本研究旨在确定抗NT 5C 1A阳性的DM、PM、IBM或其他系统性自身免疫性疾病患者的患病率和临床特征。我们在IBM、DM、PM、干燥综合征（SS）或系统性红斑狼疮（SLE）患者和健康志愿者中筛选抗NT 5C 1A自身抗体。比较抗NT 5C 1A阳性和阴性患者的临床特征。在117例IBM患者中有71例（61%）、42例PM患者中有2例（5%）、42例健康志愿者中有2例（5%）、159例DM患者中有24例（15%）、44例SS患者中有10例（23%）和96例SLE患者中有13例（14%）检测到抗NT 5C 1A自身抗体。无抗NT 5C 1A抗体阳性的SS或SLE患者有肌肉受累。抗NT 5C 1A阳性的IBM患者的边缘空泡患病率较低（62%对83%的抗体阴性患者; P = 0.02）。抗体阳性和抗体阴性的DM、SS或SLE患者的临床特征无差异。抗NT 5C 1A是循环自身抗体的常见靶标，尤其是在IBM中，但也在几种不同的自身免疫性疾病中。在SLE和SS中，抗NT 5C 1A自身反应性与肌肉疾病无关。
Prior investigations demonstrated that autoantibodies recognizing cytosolic 5′-nucleotidase 1A (NT5C1A) are found in 33–76% of patients with inclusion body myositis (IBM) but are observed only rarely in patients with polymyositis (PM). Thus, anti-NT5C1A may help distinguish IBM from PM. Although 4–21% of patients with dermatomyositis (DM) were shown to be anti-NT5C1A antibody positive, the clinical features of anti-NT5C1A–positive patients with DM have not been described. Furthermore, the prevalence of anti-NT5C1A antibodies in other rheumatic conditions has not been reported. This study was undertaken to define the prevalence and clinical features of anti-NT5C1A–positive patients with DM, PM, IBM, or other systemic autoimmune diseases. We screened for anti-NT5C1A autoantibodies in patients with IBM, DM, PM, Sjögren’s syndrome (SS), or systemic lupus erythematosus (SLE) and in healthy volunteers. Clinical characteristics were compared between patients who were anti-NT5C1A positive and those who were anti-NT5C1A negative. Anti-NT5C1A autoantibodies were detected in 71 (61%) of 117 patients with IBM, 2 (5%) of 42 patients with PM, 2 (5%) of 42 healthy volunteers, 24 (15%) of 159 patients with DM, 10 (23%) of 44 patients with SS, and 13 (14%) of 96 patients with SLE. No anti-NT5C1A antibody–positive patients with SS or SLE had muscle involvement. Anti-NT5C1A–positive patients with IBM had a lower prevalence of rimmed vacuoles (62% versus 83% of antibody-negative patients; P = 0.02). No differences in the clinical characteristics of antibody-positive and antibody-negative patients with DM, SS, or SLE were observed. Anti-NT5C1A is a common target of circulating autoantibodies, especially in IBM but also in several different autoimmune diseases. In SLE and SS, anti-NT5C1A autoreactivity is not associated with muscle disease.